Amlodipine (as besylate) with valsartan and hydrochlorothiazide
Brand: Exforge HCT®
PBAC's latest decision on Amlodipine (as besylate) with valsartan and hydrochlorothiazide: Recommended with restriction (2010). Considered for Hypertension in a patient who is not adequately controlled with any two of the drugs in the combination.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
patients who are not adequately controlled with any two of the drugs in the combination (amlodipine, valsartan and hydrochlorothiazide)
Therapy area
Cardiovascular
Evidence base
RCT
Primary endpoint
BP control rates
Key trials
VEA489A2302, Study 2305, Study 2306
Comparator
amlodipine, valsartan and hydrochlorothiazide given concomitantly (three component products)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated